Effects of the antidepressant mianserin in zebrafish: molecular markers of endocrine disruption.
Due to their environmental occurrence and intrinsic biological activity, human pharmaceuticals have received increasing attention from environmental and health agencies. Of particular, ecotoxicological concern are drugs that affect nervous- and endocrine-systems. Zebrafish genome-wide oligo arrays are used to collect mechanistic information on mianserin-induced changes in gene expression in zebrafish. Gene expression analysis in brain and gonad tissue clearly demonstrated the estrogenic activity of mianserin and its potency to disrupt normal endocrine (estrogenic) signaling, based on induction of molecular biomarkers of estrogenicity (e.g., vitellogenin1 and zona pellucida proteins). The possible mechanism underlying this estrogenic activity of mianserin is disturbance of the Hypothalamo-Pituitary-Gonadal (HPG) axis by direct interference of mianserin with the serotonergic and adrenergic systems in the brain of zebrafish. Taking into account the importance of the HPG-axis, and considering the concept of 'critical window of exposure', our results reveal the importance for more elaborate testing of endocrine disruptive effects of aquatic antidepressants at different lifestages and during longer exposure periods (e.g., life cycle studies). Although there is a low concordance between the gene expression results in this study and previous cDNA microarray hybridizations, the global mechanistic expression patterns are similar in both platforms. This argues in favor of pathway-driven analysis of gene expression results compared to gene-per-gene analysis.
van der Ven
Karlijn
K
Department of Biology, Laboratory of Ecophysiology, Biochemistry and Toxicology, University of Antwerp, Groenenborgerlaan 171, 2020 Antwerp, Belgium. Karlijn.vanderven@ua.ac.be
Keil
Dorien
D
Moens
Lotte N
LN
Hummelen
Paul Van
PV
van Remortel
Piet
P
Maras
Marleen
M
De Coen
Wim
W
D000818:Animals; D000928:Antidepressive Agents / Q000009:adverse effects*; D015415:Biomarkers / Q000032:analysis; D001921:Brain / Q000187:drug effects; D004625:Embryo, Nonmammalian / Q000187:drug effects; D052244:Endocrine Disruptors / Q000009:adverse effects*; D005260:Female; D005786:Gene Expression Regulation / Q000187:drug effects*; D008297:Male; D008803:Mianserin / Q000009:adverse effects*; D020411:Oligonucleotide Array Sequence Analysis; D010053:Ovary / Q000187:drug effects; D016133:Polymerase Chain Reaction / Q000379:methods; D013737:Testis / Q000187:drug effects; D014819:Vitellogenins / Q000187:drug effects / Q000235:genetics; D015027:Zebrafish / Q000196:embryology / Q000378:metabolism*; D029961:Zebrafish Proteins / Q000187:drug effects / Q000235:genetics
D000928:Antidepressive Agents; D015415:Biomarkers; D052244:Endocrine Disruptors; D014819:Vitellogenins; D029961:Zebrafish Proteins; D008803:Mianserin